After spending 15 years at Cambridge University leading an internationally-recognised laboratory investigating the causes of coronary heart disease, David founded Funxional Therapeutics, where he became the Chief Scientific Officer, developing FX125L, a novel anti-inflammatory agent for the treatment of asthma and other diseases with a chronic inflammatory component. Following the sale of FX125L in July 2012, David joined Index Ventures as a Venture Partner, where he was responsible for the creation, development and sale of XO1 and the creation of E3Bio.
Simon completed his undergraduate training at Guy’s, King’s and St Thomas’ School of Medicine, and began his training in anaesthesia and intensive care in south London, before undertaking an Academic Clinical Fellowship in the north central London School of Anaesthesia. He completed his PhD at Imperial College, London during which he explored the role of regulators of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine, in sepsis. Simon joined the University of Cambridge in 2016 to undertake an NIHR Academic Clinical Lecturer post combining clinical practice in anaesthesia and intensive care with the development of his research programme investigating the mechanisms of vascular dysfunction in sepsis
James read Biology at the University of Exeter before studying for a PhD in Biochemistry at the Royal Postgraduate Medical School in London. In 1997 James joined the laboratory of Professor Patrick Vallance at University College London and began working on mechanisms that regulate nitric oxide production. James moved from UCL to the MRC London Institute of Medical Sciences in 2009 before taking up the position of Professor of Molecular Medicine in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow in 2017.
Bob has more than 30 years experience developing a range of drug product candidates in both large and small companies. He was VP Research and Development at Funxional Therapeutics, where he was responsible for guiding FX125L from discovery through to Phase 2 clinical trials. Bob was Chief Operating Officer at XO1 and Stealthyx, and is presently Chief Operating Officer at SuperX Ltd. Bob is responsible for all aspects of development at Critical Pressure.